

AMENDMENT TO THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the application:

- 1-25: (Canceled)
26. (Currently Amended) A method for treating hemorrhoid disease in a human in need thereof, comprising administering to said human an effective amount of a pharmaceutical composition, said composition ~~comprising~~ consisting essentially of a thrombolytic protein selected from the group consisting of tissue-type plasminogen activator (t-PA), urokinase (u-PA), streptokinase (SK), or a combination thereof, wherein the pharmaceutical composition is administered rectally.
27. (Previously Presented) The method according to claim 26, wherein the pharmaceutical composition comprises recombinant streptokinase and a pharmacologically acceptable diluent carrier or excipient.
28. (Previously Presented) The method according to claim 27, wherein the recombinant streptokinase has a concentration of 50,000 to 1,500,000 IU per gram of the pharmaceutical composition.
29. (Previously Presented) The method according to claim 26, wherein the pharmaceutical composition further comprises ethylenediaminetetraacetic acid (EDTA).
30. (Previously Presented) The method according to claim 26, wherein the pharmaceutical composition further comprises sodium diclofenac.
31. (Previously Presented) The method according to claim 26, wherein the pharmaceutical composition further comprises sodium salicylate.

Application Serial No.: 10/540,296

Filing Date: January 20, 2006

Docket: 976-28 PCT/US

Response to Final Office Action issued June 20, 2008

Page 3 of 7

32. (Cancelled)

33. (Currently Amended) The method according to claim ~~32~~ 26, wherein the pharmaceutical composition is a suppository.